Mental Retardation
Welcome,         Profile    Billing    Logout  
 109 Companies   17 Products   17 Products   10 Mechanisms of Action   909 Trials   98763 News 


«12...17161717171817191720172117221723172417251726...17431744»
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Assessing and Addressing Behaviors in Children With Hearing Loss (clinicaltrials.gov) -  Feb 12, 2019   
    P=N/A,  N=24, Completed, 
    Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Sep 2016 | Trial primary completion date: Dec 2018 --> Sep 2016
  • ||||||||||  Enrollment open, Phase classification, Enrollment change, Trial initiation date:  EMDR in Psychiatric Inpatients With Severe Mental Disorder (clinicaltrials.gov) -  Feb 6, 2019   
    P2,  N=71, Recruiting, 
    Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Sep 2016 | Trial primary completion date: Dec 2018 --> Sep 2016 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 | N=40 --> 71 | Initiation date: Sep 2018 --> Feb 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date:  The Oral Accessibility Spatula (Spatule SAB) (clinicaltrials.gov) -  Feb 5, 2019   
    P=N/A,  N=200, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 | N=40 --> 71 | Initiation date: Sep 2018 --> Feb 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Mar 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial suspension:  Study of Structural Imaging (clinicaltrials.gov) -  Feb 1, 2019   
    P=N/A,  N=76, Suspended, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Mar 2019 N=250 --> 76 | Recruiting --> Suspended
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  RAHND: Retinoic Acid Homeostasis in Neuropsychiatric Diseases (clinicaltrials.gov) -  Jan 31, 2019   
    P=N/A,  N=200, Recruiting, 
    Recruiting --> Completed | N=20 --> 223 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Dec 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia (clinicaltrials.gov) -  Jan 30, 2019   
    P=N/A,  N=138, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Dec 2019 Trial completion date: Nov 2019 --> May 2021 | Trial primary completion date: Jun 2019 --> Dec 2020
  • ||||||||||  Trial completion date, Trial primary completion date:  Mapping the Phenotype in Adults With Phelan-McDermid Syndrome (clinicaltrials.gov) -  Jan 30, 2019   
    P=N/A,  N=30, Recruiting, 
    Trial completion date: Nov 2019 --> May 2021 | Trial primary completion date: Jun 2019 --> Dec 2020 Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Enrollment change, Trial termination:  Enhanced Medication Reconciliation For Serious Mental Illness (clinicaltrials.gov) -  Jan 25, 2019   
    P=N/A,  N=26, Terminated, 
    Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 N=150 --> 26 | Recruiting --> Terminated; Enrollment rate insufficient to fully enroll study within the planned timeline.
  • ||||||||||  NN1213 / Novo Nordisk
    Biomarker, Enrollment open:  Biomarker for Creatine Deficiency Syndromes (BioCDS) (clinicaltrials.gov) -  Jan 23, 2019   
    P=N/A,  N=1000, Recruiting, 
    N=150 --> 26 | Recruiting --> Terminated; Enrollment rate insufficient to fully enroll study within the planned timeline. Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  DSPP-PSY: Improving Access to Psychiatric Care for Patients in Primary Care (clinicaltrials.gov) -  Jan 23, 2019   
    P=N/A,  N=240, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2020 --> Sep 2020 | Trial primary completion date: Feb 2019 --> Jun 2019
  • ||||||||||  Trial completion, Enrollment change, Trial completion date:  VIP: Vanderbilt ICU Recovery Program Pilot Trial (clinicaltrials.gov) -  Jan 11, 2019   
    P=N/A,  N=232, Completed, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed | N=550 --> 232 | Trial completion date: Oct 2018 --> Apr 2018
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  EUMAP: European Alpha-Mannosidosis Participant (clinicaltrials.gov) -  Jan 10, 2019   
    P=N/A,  N=1000, Recruiting, 
    Trial completion date: Dec 2018 --> Jul 2019 | Trial primary completion date: Dec 2018 --> Jul 2019 Not yet recruiting --> Recruiting | Trial completion date: Aug 2020 --> Dec 2019 | Trial primary completion date: Aug 2020 --> Dec 2019
  • ||||||||||  Enrollment closed:  Mindfulness-based Program for Children With Disruptive Behavior Disorder (clinicaltrials.gov) -  Jan 10, 2019   
    P=N/A,  N=60, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2020 --> Dec 2019 | Trial primary completion date: Aug 2020 --> Dec 2019 Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  Effects of Delta-9-THC and Iomazenil in Healthy Humans (clinicaltrials.gov) -  Jan 9, 2019   
    P1,  N=60, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies (clinicaltrials.gov) -  Jan 9, 2019   
    P=N/A,  N=450, Recruiting, 
    Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 N=150 --> 450 | Trial completion date: Apr 2020 --> Aug 2019 | Trial primary completion date: Oct 2018 --> Aug 2019
  • ||||||||||  Journal:  Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. (Pubmed Central) -  Jan 9, 2019   
    Contiguous gene deletions have been described in other inherited cancer predisposition syndromes, such as Familial Adenomatous Polyposis. Our report and review of the literature suggests that contiguous gene deletion within the 2p16-p21 chromosomal region is a rare cause of Lynch syndrome, but presents with distinct phenotypic features, highlighting the need for recognition and awareness of this syndromic entity.
  • ||||||||||  Enrollment closed:  Tobacco Intensive Motivational and Estimate Risk (clinicaltrials.gov) -  Jan 8, 2019   
    P=N/A,  N=230, Active, not recruiting, 
    Our report and review of the literature suggests that contiguous gene deletion within the 2p16-p21 chromosomal region is a rare cause of Lynch syndrome, but presents with distinct phenotypic features, highlighting the need for recognition and awareness of this syndromic entity. Recruiting --> Active, not recruiting